Active — Not RecruitingNot Applicable

Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules

United States328 participantsStarted 2016-05-01

Plain-language summary

The purpose of this study is to compare the performance of Afirma GSC and ThyroSeq v.3 in indeterminate thyroid nodules to determine which test can allow more patients to avoid unnecessary surgery and preserve quality of life. In the initial phase of this study, the performance of Afirma GEC and ThyroSeq v.2 were compared.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with a thyroid nodule who have a thyroid biopsy performed at UCLA health will be eligible for the study and consented if they agree to participate. * Patients who have an indeterminate FNA biopsy result (Bethesda category 3 or 4) will be enrolled in the study if they agree to participate. Exclusion Criteria: * Patients who do not have an indeterminate biopsy result (either patients who have a benign, insufficient, or malignant result).

What they're measuring

Afirma GEC vs. ThyroSeq v.2 in indeterminate thyroid nodules post best practices surgery

Timeframe: 12 months. [This phase of the study is now completed]

2. Afirma GSC vs. ThyroSeq v.3 in indeterminate thyroid nodules post best practices surgery

Timeframe: 12 months.

Trial details

NCT IDNCT02681328

SponsorJonsson Comprehensive Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-01

View on ClinicalTrials.gov More Thyroid trials